CL2018002602A1 - Composición y método para el tratamiento del deterioro cognitivo. - Google Patents
Composición y método para el tratamiento del deterioro cognitivo.Info
- Publication number
- CL2018002602A1 CL2018002602A1 CL2018002602A CL2018002602A CL2018002602A1 CL 2018002602 A1 CL2018002602 A1 CL 2018002602A1 CL 2018002602 A CL2018002602 A CL 2018002602A CL 2018002602 A CL2018002602 A CL 2018002602A CL 2018002602 A1 CL2018002602 A1 CL 2018002602A1
- Authority
- CL
- Chile
- Prior art keywords
- percent
- composition
- weight
- treatment
- cognitive impairment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
LA PRESENTE INVENCIÓN, EN LAS REALIZACIONES, ES UNA COMPOSICIÓN Y MÉTODO DE TRATAMIENTO QUE USA UNA COMPOSICIÓN QUE INCLUYE: UN PRIMER COMPONENTE QUE COMPRENDE: 75 A 97 POR CIENTO EN PESO DE TRIGLICÉRIDOS DE CADENA MEDIA; EN DONDE LOS TRIGLICÉRIDOS DE CADENA MEDIA COMPRENDEN ÉSTERES DE ÁCIDO GRASO DE GLICEROL DE 6 A 12 ÁTOMOS DE CARBONO; 4 A 15 POR CIENTO EN PESO DE LECITINA DE SOYA; 0,05 A 1 POR CIENTO EN PESO DE BIOTINA Y 0,01 A 0,2 POR CIENTO EN PESO DE ANTIOXIDANTE, Y ACEITE DE OLIVA, EN DONDE EL ANTIOXIDANTE SE SELECCIONA DEL GRUPO QUE CONSISTE EN TOCOFEROL, PALMITATO DE ASCORBILO, EXTRACTO DE ROMERO Y MEZCLAS DE LOS MISMOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307714P | 2016-03-14 | 2016-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002602A1 true CL2018002602A1 (es) | 2018-11-30 |
Family
ID=58993159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002602A CL2018002602A1 (es) | 2016-03-14 | 2018-09-11 | Composición y método para el tratamiento del deterioro cognitivo. |
Country Status (7)
Country | Link |
---|---|
US (1) | US10869852B2 (es) |
EP (1) | EP3429578B1 (es) |
CL (1) | CL2018002602A1 (es) |
CO (1) | CO2018009407A2 (es) |
ES (1) | ES2925058T3 (es) |
MX (1) | MX2018011058A (es) |
WO (1) | WO2017158427A1 (es) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1273287A1 (en) * | 2000-04-04 | 2003-01-08 | Shionogi & Co., Ltd. | Oily compositions containing highly fat-soluble drugs |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
GB0115982D0 (en) * | 2001-06-29 | 2001-08-22 | Oaklea Ltd | Stabilisation of chlorophyll |
AU2003245468A1 (en) * | 2002-06-11 | 2003-12-22 | Pasteuria Bioscience Llc | Materials and methods for in vitro production of bacteria |
US20130017278A1 (en) * | 2011-07-13 | 2013-01-17 | Arlene Keller | Composition and method for improving brain function |
-
2017
- 2017-03-14 WO PCT/IB2017/000337 patent/WO2017158427A1/en active Application Filing
- 2017-03-14 EP EP17727369.5A patent/EP3429578B1/en active Active
- 2017-03-14 ES ES17727369T patent/ES2925058T3/es active Active
- 2017-03-14 MX MX2018011058A patent/MX2018011058A/es unknown
-
2018
- 2018-09-07 CO CONC2018/0009407A patent/CO2018009407A2/es unknown
- 2018-09-11 CL CL2018002602A patent/CL2018002602A1/es unknown
- 2018-09-12 US US16/129,580 patent/US10869852B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
MX2018011058A (es) | 2019-06-20 |
CO2018009407A2 (es) | 2018-10-22 |
US10869852B2 (en) | 2020-12-22 |
WO2017158427A1 (en) | 2017-09-21 |
EP3429578B1 (en) | 2022-08-10 |
EP3429578A1 (en) | 2019-01-23 |
ES2925058T3 (es) | 2022-10-13 |
US20190076387A1 (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018001361A1 (es) | Inhibidores éster de acc y usos de los mismos | |
CL2017002830A1 (es) | Acidos grasos poliinsaturados de cadena muy larga a partir de aceites naturales. | |
CO2019000672A2 (es) | Procedimiento de tratamiento de dismenorrea y dolor menstrual | |
BR112016023851A2 (pt) | ?composição de revestimento de duas partes e método para revestir uma superfície? | |
BR112016025504A2 (pt) | composições para cuidado de lavanderia | |
AR098893A1 (es) | Proceso para obtener aceite microbiano a partir de células microbianas | |
CL2021000635A1 (es) | Composición sólida que comprende un componente oleoso comprendiendo uno o más aceites y un componente lipídico comprendiendo uno o más lípidos; su método de preparación (div. sol. 202000918). | |
PE20200223A1 (es) | Una composicion bioestimulante a base de taninos y/o sus derivados, para el tratamiento de plantas cultivadas y/o partes de las mismas | |
CO2019005156A2 (es) | Composición para el tratamiento y/o prevención de la enfermedad fúngica sigatoka negra en los cultivos de banana | |
EA201992520A1 (ru) | Масло, улучшающее композицию для кожи | |
BR112015020832A2 (pt) | composição de sulfonato de olefina interna, e, método para tratamento de uma formação contendo petróleo bruto | |
AR091872A1 (es) | Intraesterificacion aleatoria | |
CL2021001474A1 (es) | Una composición que contiene un ácido graso altamente insaturado o un éster alquílico del mismo y un método para la producción del mismo | |
AR112466A1 (es) | Complejo cosmético para la hidratación bioactiva, composición cosmética, uso y método | |
BR112019021452A8 (pt) | Composição aglutinante, artigo, e método para fabricar um artigo | |
AR092759A1 (es) | Formulaciones en forma de nanodispersiones no acuosas de taxanos y metodos para usarlas | |
BR112018077510A2 (pt) | variantes de lipase e composições que compreendem tensoativo e variante de lipase | |
CL2018002602A1 (es) | Composición y método para el tratamiento del deterioro cognitivo. | |
AR094913A1 (es) | Transporte de petróleo pesado | |
BR112014017048A8 (pt) | emulsão orgânica compreendendo dha e epa | |
BR112017005759A2 (pt) | composição de preparação externa que contém s-flurbiprofeno | |
CL2017001472A1 (es) | Composiciones y métodos que comprenden triglicéridos de cadena media para el tratamiento de la epilepsia. | |
CL2017002828A1 (es) | Composición para tratamiento de estrés oxidativo y enfermedad cardiovascular | |
CL2019001338A1 (es) | Preparación cosmética de viscosidad mejorada para el tratamiento de las fibras queratínicas, proceso para el aumento de la viscosidad de una preparación cosmética, uso de ingredientes modificadores de la viscosidad y método de tratamiento de las fibras queratínicas. | |
BR112016029165A2 (pt) | método para degomagem de composições contendo triglicerídeos |